The drug historically used to diagnose myasthenia gravis before treating it is edrophonium chloride, sold under the brand name Tensilon. Introduced in 1952, this short-acting acetylcholinesterase inhibitor became the cornerstone of MG diagnosis for more than six decades. A physician would inject edrophonium intravenously, and if a patient’s drooping eyelids suddenly lifted or their grip strength noticeably improved within a minute, that rapid but fleeting response pointed squarely toward myasthenia gravis. The test was elegant in its simplicity — a drug that worked for only five to ten minutes could reveal a disease that lasted a lifetime. But the Tensilon test is no longer the standard.
In 2018, the U.S. FDA discontinued approval for edrophonium as a diagnostic tool, citing false-positive results, the risk of serious cardiac side effects, and the emergence of better alternatives. Today, clinicians rely on antibody blood tests, electrodiagnostic studies, and even something as low-tech as an ice pack placed over a closed eyelid. The shift away from edrophonium reflects a broader trend in neurology — moving from bedside provocation tests toward laboratory precision. This article covers how edrophonium worked at the neuromuscular junction, the exact procedure physicians followed when administering the test, what a large 2026 retrospective study revealed about its true diagnostic accuracy, why regulators pulled it from the market, and what has replaced it. For caregivers and families navigating a new MG diagnosis — particularly those already managing overlapping neurological conditions like dementia — understanding this history matters, because it shapes what diagnostic pathway a neurologist will follow today.
Table of Contents
- What Drug Was Used to Diagnose Myasthenia Gravis Before Treatment Began?
- How the Tensilon Test Was Performed and What Its Limitations Were
- What a 2026 Retrospective Study Revealed About Edrophonium’s Accuracy
- What Replaced the Tensilon Test and How Current MG Diagnosis Compares
- Risks, Warnings, and Why Older Adults Face Special Diagnostic Challenges
- Pyridostigmine — The Treatment Drug That Followed Diagnosis
- The Future of MG Diagnosis and What Families Should Know
- Conclusion
- Frequently Asked Questions
What Drug Was Used to Diagnose Myasthenia Gravis Before Treatment Began?
Edrophonium chloride belongs to a class of drugs called acetylcholinesterase inhibitors. In myasthenia gravis, the immune system attacks acetylcholine receptors at the neuromuscular junction — the point where nerves communicate with muscles. With fewer working receptors, the chemical messenger acetylcholine gets broken down by the enzyme acetylcholinesterase before it can do its job, and muscles weaken. Edrophonium temporarily blocks that enzyme, allowing acetylcholine to accumulate and bind to whatever receptors remain. The result, in someone with MG, is a brief but noticeable improvement in muscle strength. What made edrophonium useful as a diagnostic agent rather than a treatment was its extremely short duration.
The drug’s effects lasted only about five to ten minutes — long enough to observe whether weakness improved, but far too brief to serve as ongoing therapy. Compare this with pyridostigmine bromide (brand name Mestinon), the acetylcholinesterase inhibitor actually used to treat MG after diagnosis. Pyridostigmine is taken orally and its effects last for hours, making it practical for daily symptom management. Edrophonium and pyridostigmine work through the same basic mechanism, but one was built for a quick diagnostic snapshot and the other for sustained relief. The distinction matters for families dealing with overlapping neurological conditions. A person with dementia who develops new-onset ptosis or difficulty swallowing may need evaluation for MG, and understanding that the old go-to diagnostic drug is no longer available helps set expectations for what the workup will actually look like today.
How the Tensilon Test Was Performed and What Its Limitations Were
The Tensilon test followed a careful two-step intravenous protocol. A physician would first inject 2 mg of edrophonium and watch the patient for roughly sixty seconds, monitoring for adverse reactions. If nothing alarming occurred — no sudden drop in heart rate, no breathing difficulty — an additional 8 mg was administered, bringing the total dose to 10 mg. The clinician would then observe specific muscle groups, often the eyelids or extraocular muscles, for rapid improvement. A patient whose severe ptosis suddenly resolved within a minute was considered to have a positive result. However, the test was far from perfect.
A positive response did not guarantee MG, and a negative response did not rule it out. False positives could occur in other neuromuscular conditions, including Lambert-Eaton myasthenic syndrome and certain motor neuron diseases. If a patient had purely subjective weakness or if the examiner was not blinded to the injection timing, interpretation became even murkier. The test also required emergency resuscitation equipment to be immediately available in the room — crash cart, atropine on hand, cardiac monitoring — because of the risk of bradycardia, hypotension, bronchospasm, and in rare cases, cardiac arrest. For elderly patients or those with existing cardiac conditions, the risk calculus was particularly unfavorable. These limitations accumulated over decades. By the time the FDA pulled its approval in 2018, the medical community had largely acknowledged that the Tensilon test’s subjective interpretation and safety profile made it an increasingly difficult tool to justify when better options existed.
What a 2026 Retrospective Study Revealed About Edrophonium’s Accuracy
A retrospective study published in 2026 through PMC provided one of the most comprehensive modern evaluations of the edrophonium test’s diagnostic performance. Researchers examined 182 confirmed MG cases alongside 324 controls and found that the test achieved a sensitivity of 83.5% and a specificity of 87.7%. In practical terms, this means the test correctly identified about 84 out of every 100 people who actually had MG, while correctly ruling it out in roughly 88 out of every 100 people who did not. The study also revealed an important nuance: sensitivity climbed to 88.4% in patients who showed a decrement on repetitive nerve stimulation testing, compared with only 66.7% in those without that electrodiagnostic finding. This suggests the Tensilon test worked best when there was already objective electrophysiological evidence of neuromuscular junction dysfunction — somewhat undermining its value as a standalone screening tool.
If you needed another test to confirm the conditions under which the Tensilon test performed well, the argument for using it as a first-line diagnostic weakened considerably. On the safety front, the study reported that 11.5% of patients experienced adverse events during the test. The reassuring detail was that 91.4% of those events were mild — vertigo, muscle cramping, excessive tearing, nausea, and sweating. Only one patient in the study experienced a severe adverse event. While that rate sounds low in a research context, the prospect of a serious cardiac event during what is essentially a diagnostic screening test was enough to keep clinicians wary, especially when safer alternatives had become widely available.
What Replaced the Tensilon Test and How Current MG Diagnosis Compares
The first-line diagnostic approach for myasthenia gravis today is serological antibody testing. Clinicians check for acetylcholine receptor (AChR) antibodies, which are positive in up to 90% of patients with generalized MG. For the subset of patients who test negative for AChR antibodies, testing for MuSK (muscle-specific kinase) antibodies and LRP4 (lipoprotein-related protein 4) antibodies can catch additional cases. The tradeoff is that antibody testing is less reliable in ocular MG, where AChR antibodies are found in only 50 to 70% of patients, leaving a meaningful diagnostic gap. Electrodiagnostic studies fill part of that gap.
Repetitive nerve stimulation (RNS) looks for a characteristic decrementing response when a nerve is stimulated repeatedly, while single-fiber electromyography (SFEMG) measures the variability in transmission time at individual neuromuscular junctions. SFEMG is the most sensitive electrodiagnostic test for MG, but it requires specialized equipment and expertise that not every medical center has available, creating access disparities — particularly for patients in rural settings or those whose mobility is already compromised by conditions like dementia. One of the most surprising replacements is the ice pack test, a bedside technique that involves placing an ice pack over a closed eyelid for two to five minutes and then checking whether ptosis has improved. Cold temperatures inhibit acetylcholinesterase activity, mimicking the pharmacological effect of edrophonium without any drug at all. Studies have demonstrated 76.9% sensitivity at two minutes and 98.3% specificity at five minutes. The ice pack test costs almost nothing, carries no cardiac risk, and requires no resuscitation equipment — a striking contrast to the infrastructure the Tensilon test demanded.
Risks, Warnings, and Why Older Adults Face Special Diagnostic Challenges
For older adults, particularly those with coexisting cognitive decline or dementia, MG diagnosis presents unique challenges regardless of which method is used. The Tensilon test’s reliance on observable, objective improvement in specific muscle groups could be confounded by a patient’s inability to follow commands or cooperate with the examination. A person with moderate Alzheimer’s disease who cannot reliably perform repetitive grip testing or sustained upward gaze on command makes subjective bedside tests — whether pharmacological or physical — harder to interpret. Antibody testing sidesteps this problem because it requires only a blood draw, but clinicians should be aware of a critical limitation: seronegative myasthenia gravis. Approximately 10 to 15% of MG patients test negative for all known antibodies.
In these cases, electrodiagnostic studies become essential, but SFEMG requires patient cooperation to maintain a steady voluntary muscle contraction — again, a potential barrier for someone with significant cognitive impairment. Families and caregivers should advocate for comprehensive testing rather than accepting a single negative antibody result as definitive, especially when clinical suspicion is high. There is also the matter of medication interactions. Many drugs commonly used in dementia care — including certain cholinesterase inhibitors like donepezil and rivastigmine — work through a mechanism related to edrophonium’s. While these drugs target acetylcholinesterase in the brain rather than at the neuromuscular junction, their presence can theoretically complicate interpretation of both diagnostic tests and early treatment responses. Neurologists evaluating a dementia patient for possible MG need a complete medication list to avoid confounded results.
Pyridostigmine — The Treatment Drug That Followed Diagnosis
Once MG is confirmed, the standard first-line treatment is pyridostigmine bromide, marketed as Mestinon. Like edrophonium, pyridostigmine is an acetylcholinesterase inhibitor, but it is designed for sustained oral use rather than a one-time intravenous diagnostic injection. Patients typically take pyridostigmine multiple times daily, and its effects last several hours per dose, providing ongoing improvement in muscle strength and endurance.
The relationship between edrophonium and pyridostigmine illustrates a principle worth understanding: the same pharmacological mechanism can serve completely different clinical purposes depending on how the drug is formulated and delivered. Edrophonium’s five-to-ten-minute window was a feature for diagnosis and a limitation for treatment. Pyridostigmine’s longer duration makes it impractical as a diagnostic tool — you cannot easily distinguish a brief diagnostic response from the drug’s sustained therapeutic effect — but ideal for helping patients manage daily activities like chewing, swallowing, and breathing.
The Future of MG Diagnosis and What Families Should Know
The trajectory of MG diagnosis points toward greater precision and less reliance on provocative testing. Research into novel biomarkers, including complement activation products and cytokine profiles, may eventually identify MG subtypes with even greater accuracy than current antibody panels. For families managing both MG and dementia in the same household — or in the same patient — these advances could reduce the number of specialist visits, invasive tests, and diagnostic delays that currently characterize the workup.
Chest imaging with CT or MRI also remains part of the diagnostic pathway, since roughly 10 to 15% of MG patients have a thymoma, a tumor of the thymus gland whose removal can significantly improve MG symptoms. For caregivers navigating an already complex medical landscape, the key takeaway is that MG diagnosis no longer depends on a single drug test with a narrow safety margin. The tools available today are safer, more accessible, and in most cases more accurate than the Tensilon test ever was.
Conclusion
Edrophonium chloride served as the primary diagnostic drug for myasthenia gravis for more than sixty years, offering clinicians a rapid, observable way to confirm neuromuscular junction dysfunction at the bedside. Its discontinuation in 2018 was not a failure of the drug itself but a reflection of medicine’s ability to develop safer and more precise alternatives — antibody panels, electrodiagnostic studies, and even a simple ice pack test that achieves remarkable specificity without any pharmacological risk.
For families and caregivers, especially those already managing conditions like dementia, the practical lesson is that MG evaluation today is a multi-step process rather than a single pass-or-fail injection. Knowing that seronegative MG exists, that ocular MG may not show antibodies, and that cognitive impairment can complicate certain tests empowers caregivers to ask informed questions and push for thorough workups. If MG is suspected, request a referral to a neuromuscular specialist who can coordinate antibody testing, electrodiagnostics, and imaging into a coherent diagnostic plan.
Frequently Asked Questions
Is the Tensilon test still available anywhere?
Edrophonium chloride lost FDA approval for MG diagnosis in 2018, and commercial production of Tensilon has been discontinued in the United States. Some medical centers outside the U.S. may still have access to edrophonium, but it is no longer considered a standard diagnostic tool in current clinical guidelines.
Can the ice pack test replace the Tensilon test for diagnosing MG?
The ice pack test is useful specifically for evaluating ptosis (drooping eyelids) and has shown 76.9% sensitivity at two minutes and 98.3% specificity at five minutes. However, it cannot assess other forms of muscle weakness and is most valuable as one component of a broader diagnostic workup rather than a standalone replacement.
What happens if MG antibody tests come back negative?
Approximately 10 to 15% of MG patients are seronegative, meaning they test negative for AChR, MuSK, and LRP4 antibodies. In these cases, electrodiagnostic studies — particularly single-fiber electromyography — become critical. A negative antibody test alone does not rule out MG.
Is myasthenia gravis related to dementia or Alzheimer’s disease?
MG and dementia are distinct conditions affecting different parts of the nervous system — MG targets the neuromuscular junction while dementia involves brain degeneration. However, they can coexist in the same patient, particularly in older adults, and some symptoms like difficulty swallowing or facial weakness can overlap, making careful differential diagnosis important.
How long does it take to get an MG diagnosis today?
With antibody blood tests, results typically return within a few days to two weeks depending on the laboratory. Electrodiagnostic testing can be performed in a single clinic visit. However, diagnostic delays remain common — some studies suggest an average delay of one to two years from symptom onset to confirmed diagnosis, particularly for patients with mild or purely ocular symptoms.
